2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5934 Feasibility and safety of fecal microbiota transplantation with or without a microbiome-optimized diet in CAR-T recipients

Charan Thej Reddy Vegivinti, MD, MBBS, Gabriela Rodriguez Mendez2, Abdur Rehman3, Faezeh Darbaniyan, PhD4, Luis Malpica, MD5, Pranoti Sahasrabhojane6, Paolo Strati, MD7, Ranjit Nair, MD8, Dai Chihara, MD, PhD9, Luis E. Fayad, MD10, Sairah Ahmed, MD11, Fateeha Furqan, MBBS12, Michael Wang, MD13, Swaminathan P. Iyer, MD14, Donna Marie Weber, MD15, Melody Renee Becnel, MD16, Oren Pasvolsky, MD17, Sarvari V. Yellapragada, MD18, Mahmoud R. Gaballa, MD19, Sheeba Koshy Thomas, M.D.20, Meera Mohan, MD, MS21, Qaiser Bashir, MD22, Samer A Srour, MB ChB, MS23, Muzaffar Qazilbash, MD24, Robert Orlowski, MD, PhD25, Jing Christine Ye, M.D., MSc26, Nadim Ajami27, Sattva S Neelapu Sr, MD28, Richard Champlin29, Christopher R. Flowers Jr, MD, MS30, Elizabeth Shpall, MD31, Zhi-Dong Jiang, MD, DrPh32, Herbert L Dupont, MD33, Ruitao Lin, PhD34, Jason Westin, MD, MS, FACP, FASCO35, Carrie Daniel-MacDougall36, Krina Patel Jr, MD, MSc37, Neeraj Saini, MD38
1 The University of Texas MD Anderson Cancer, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer, Houston, Texas, United States
31 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
32 University of Texas, Houston, Texas, United States
33 University of Texas School of Public Health, Houston, Texas, United States
34 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
35 The University of Texas MD Anderson Cancer, Houston, Texas, United States
36 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
37 The University of Texas MD Anderson Cancer, Houston, Texas, United States
38 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States, The University of Texas MD Anderson Cancer, Houston, Texas, United States

Background: The gut microbiome has been associated with both efficacy and toxicity of CAR T-cell therapy, but these findings are largely observational, and no causal relationship has been established. The safety of microbiome-directed interventions in CAR T-cell recipients remains unknown. Diet is a major modifiable factor shaping gut microbial composition, and a fiber- and prebiotic-rich diet may promote a favorable environment supporting engraftment and persistence of transplanted microbiota. We therefore initiated a randomized trial of fecal microbiota transplantation (FMT), with or without the BIOME (Balanced Diet for Optimal Microbial Ecology) diet, and report initial safety and feasibility findings in patients receiving CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL) or multiple myeloma (MM) (NCT06218602).

Methods: Adults with R/R LBCL (axicabtagene ciloleucel) or MM (ciltacabtagene autoleucel) planned for standard-of-care CAR T-cell therapy were randomized 2:2:1 to Arm A, FMT alone (N=16); Arm B, placebo (N=32); or Arm C, FMT plus the BIOME diet (N=32); target 80. Enrollment initially opened to lymphoma (first 3 patients), then switched to MM given slow accrual. Primary objective: toxicity assessment of FMT + BIOME diet with SOC (Arm C) vs. placebo + SOC CAR-T (Arm B). Secondary objectives: day 30 response, PFS/OS at1, 3, 6, and 12 months, and cytopenia rates by FMT status; and FMT's effects on gut microbiome engraftment (Arm A vs. C) and serum/stool metabolomics. FMT was a fecal enema (≈50 g stool) on days −13 and −8 before infusion and 10 oral lyophilized capsules (≈1–1.5 g each) on days +14/+21/+28. The FMT product was derived from either a healthy unrelated donor or a prior CAR-T FMT-trial responder in complete remission. The placebo enema was visually identical but bacteria-free (spray-dried lactose with food coloring), as were placebo capsules. Each FMT dose required an absolute neutrophil count (ANC) >1000/µL and was withheld otherwise. AEs were graded by CTCAE v5.0 and CRS/ICANS by ASTCT criteria. 

Results: 15 (3 LBCL and 12 MM) patients were evaluable. Patients were assigned to FMT alone (n=3), placebo (n=8), or FMT plus diet (n=4). Median age was 70 years (range, 27-78). Median follow-up was 20.9 months for LBCL and 2.8 months for MM. FMT was feasible and well tolerated. Of 103 AEs, only 2 were possibly treatment-related — both grade 1 GI events (nausea, FMT arm; diarrhea, placebo). No grade ≥3 or fatal AE was FMT-attributed; there were no culture-positive infections. Overall, 47 grade ≥3 AEs occurred (in 3/3 FMT-alone, 5/8 placebo, 2/4 FMT plus diet patients). Most (35/47) were hematologic (neutropenia 16, thrombocytopenia 13, anemia 5, lymphopenia 1), consistent with post-lymphodepletion cytopenias. All grade 4 events were cytopenias; no grade 5 occurred. Non-hematologic grade ≥3 AEs were infrequent and none FMT-attributed.

In LBCL, 1 patient received FMT and 2 received placebo. The FMT-treated patient had no FMT-related adverse events (AEs), CRS, or ICANS and remains in complete response (CR) at 23 months. Of the 2 placebo-treated patients, 1 remains in CR without CRS/ICANS, whereas 1 developed grade 1 CRS and relapsed at 1 year.

Among 12 MM patients (2 FMT, 6 placebo, and 4 FMT plus diet), median 2 prior lines; 10/12 had a prior autologous transplant. Responses were high across arms: all responded, including 9/9 MM with ≥VGPR. Among MM responders, 5 achieved stringent CR, 4 VGPR, and 8/9 were MRD-negative. No progression or death had occurred in the MM cohort at data cutoff.

CRS occurred in 6/15 patients, all grade 1-2. CRS occurred in 2/7 FMT-containing patients (29%), requiring no tocilizumab or corticosteroids, vs 4/8 placebo (50%), which required tocilizumab and/or corticosteroids. No ICANS occurred (0/15).

Conclusion: In this preliminary randomized study, FMT with or without diet was feasible and safe, with no FMT-attributed serious toxicity, bacteremia, ICANS, or treatment-related mortality in CAR-T recipients. CRS was uniformly low-grade and appeared less frequent and less treatment-requiring in FMT-containing arms, a hypothesis-generating signal that microbiome modulation may attenuate CAR T-cell inflammatory toxicity. Larger cohorts, longer follow-up, and formal analysis after study completion are needed to confirm these findings and assess effects on toxicity and efficacy.

Charan Thej Reddy Vegivinti, MD, MBBS: No relevant conflicts of interest to declare.